Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 171 citing articles:

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 399, Iss. 10320, pp. 143-151
Open Access | Times Cited: 257
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 400, Iss. 10349, pp. 359-368
Open Access | Times Cited: 254
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Christian Zanza, Tatsiana Romenskaya, A Manetti, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 144-144
Open Access | Times Cited: 240
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
Oliver J. McElvaney, Gerard F. Curley, Stefan Rose‐John, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 643-654
Open Access | Times Cited: 181
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
Eric J. Rubin, Dan L. Longo, Lindsey R. Baden
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1564-1565
Open Access | Times Cited: 138
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19
Lok-Yin Roy Wong, Jian Zheng, Kevin Wilhelmsen, et al.
Nature (2022) Vol. 605, Iss. 7908, pp. 146-151
Open Access | Times Cited: 135
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19
Jeffrey S. Berger, Lucy Z. Kornblith, Michelle N. Gong, et al.
JAMA (2022) Vol. 327, Iss. 3, pp. 227-227
Open Access | Times Cited: 105
Neutrophils in COVID-19: Not Innocent Bystanders
Ellen McKenna, Richard Wubben, Johana M. Isaza-Correa, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 82
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
Nicola Potere, Marco Giuseppe Del Buono, Roberto Caricchio, et al.
EBioMedicine (2022) Vol. 85, pp. 104299-104299
Open Access | Times Cited: 78
Persistent Oxidative Stress and Inflammasome Activation in CD14highCD16− Monocytes From COVID-19 Patients
Silvia Lucena Lage, Eduardo P. Amaral, Kerry L. Hilligan, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 77
The roles of critical pro‐inflammatory cytokines in the drive of cytokine storm during SARS‐CoV‐2 infection
Muhammad Suhaib Qudus, Mingfu Tian, Summan Sirajuddin, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Open Access | Times Cited: 46
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
Saul N. Faust, Richard Haynes, Christine E. Jones, et al.
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 3, pp. 190-200
Open Access | Times Cited: 14
Comprehensive GC-MS Characterization and Histochemical Assessment of Various Parts of Three Colchicum Species from Bulgarian Flora
Ivayla Dincheva, Ilian Badjakov, Vasil Georgiev, et al.
Plants (2025) Vol. 14, Iss. 2, pp. 270-270
Open Access | Times Cited: 1
Pharmacological treatment of COVID-19: an opinion paper
Alberto García‐Lledó, Javier Gómez‐Pavón, Juan González del Castillo, et al.
Revista Española de Quimioterapia (2021) Vol. 35, Iss. 2, pp. 115-130
Open Access | Times Cited: 62
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Colchicine for the treatment of COVID-19
Agata Mikołajewska, Anna-Lena Fischer, Vanessa Piechotta, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 58
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Xue Li, Ziqi Zhang, Zhenling Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 49
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
Aldo Bonaventura, Alessandra Vecchiè, Lorenzo Dagna, et al.
Inflammation Research (2022) Vol. 71, Iss. 3, pp. 293-307
Open Access | Times Cited: 42
Social Media and COVID-19—Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics
Natalie Schellack, Morné Strydom, Michael S. Pepper, et al.
Antibiotics (2022) Vol. 11, Iss. 4, pp. 445-445
Open Access | Times Cited: 38
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis
Nicola Potere, Evan C. Garrad, Yogendra Kanthi, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 11, pp. 2046-2060
Open Access | Times Cited: 30
Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?
Maria Fernanda Pessano Fialho, Evelyne da Silva Brum, Sara Marchesan Oliveira
Inflammopharmacology (2023) Vol. 31, Iss. 2, pp. 633-651
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top